论文部分内容阅读
FDA于2007-10-12批准GlaxoSmith Kline开发的膦沙那韦钙(Lexiva片剂和口服混悬剂,1400mg,qd)与利托那韦(ritonavir,100mg)联用治疗初次接受治疗的成年HIV感染者。
The FDA approved the use of phosphinavarvate (Lexiva tablet and oral suspension, 1400 mg, qd) developed by GlaxoSmith Kline in combination with ritonavir (100 mg) for the treatment of naive HIV-infected adults Infected.